Bioequivalence of a New Cyclosporine A Formulation to Neoral®

Therapeutic Drug Monitoring

Volumn 26, Issue 1, 2004, Pages 53-57

  David Neto, Elias ^a,b   Kakehashi, Erica ^a   Alves, Cristiane Feres ^a   Pereira, Lilian M ^a   De Castro, Maria Cristina R ^a   De Mattos, Renata Maciel ^a   Sumita, Nairo Massakazu ^a   Romano, Paschoalina ^a   Mendes, Maria Elizabete ^a   Nahas, William Carlos ^a   Ianhez, Luiz Estevam ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Area under the curve; Bioequivalence; Cyclosporine A; Immunosuppression; Pharmacokinetics; Renal transplantation

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; SIGMASPORIN; ZINOGRAF ME;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CADAVER; CLINICAL ARTICLE; DRUG FORMULATION; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; MALE; PRESCRIPTION; PRIORITY JOURNAL; RECIPIENT;

ADMINISTRATION, ORAL; AREA UNDER CURVE; CYCLOSPORINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; THERAPEUTIC EQUIVALENCY;

EID: 9144256613     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200402000-00012     Document Type: Article

References (17)

1. FDA. Guidance for Industry-Bioavailability and Bioequivalence Studies for Orally Administered Drug Products: General Considerations. Washington, DC: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), 2002.
2. David-Neto E, Araujo LM, Brito ZM, et al. Sampling strategy to calculate the cyclosporin-A area under the time-concentration curve. Am J Transplant. 2002;2:546.
3. David-Neto E, Araujo LP, Feres Alves C, et al. A strategy to calculate cyclosporin A area under the time-concentration curve in pediatric renal transplantation. Pediatr Transplant. 2002;6:313.
4. Stephens MA. EDF statistics for goodness of fit and some comparisons. J Am Statist Assoc. 1974;69:730.
5. Pollard S, Nashan B, Johnston A, et al. A pharmacokinetic and clinical review of the potential clinical impact of using different formulations of cyclosporin A. Clin Ther. 2003;25:1654.
6. Christians U, First MR, Benet LZ. Recommendations for bioequivalence testing of cyclosporine generics revisited. Ther Drug Monit. 2000;22:330.
7. Canadian Neoral Renal Transplant Study. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation. Transplantation. 2001;72:1024.
8. Steimer W. Performance and specificity of monoclonal immunoassays for cyclosporine monitoring: how specific is specific? Clin Chem. 1999;45: 371.
9. Aspeslet LJ, LeGatt DF, Murphy G, et al. Effect of assay methodology on pharmacokinetic differences between cyclosporine Neoral and Sandimmune formulations. Clin Chem. 1997;43:104.
10. Lee YJ, Chung SJ, Shim CK. The potential replacement of HPLC by 125I-RIA for the characterization of cyclosporin A: a bioavailability study after oral administration in healthy human subjects. J Pharm Biomed Anal. 2000;22:183.
11. Sinescu I, Lopes HV, Foschi D, et al. New cyclosporine microemulsion randomized, cross-over bioequivalence steady-state study in renal transplanted patients. Eur Rev Med Pharmacol Sci. 1999;3:11.
12. Belitsky P, Dunn S, Johnston A, et al. Impact of absorption profiling on efficacy and safety of cyclosporin therapy in transplant recipients. Clin Pharmacokinet. 2000;39:117.
13. Mahalati K, Belitsky P, West K, et al. Approaching the therapeutic window for cyclosporine in kidney transplantation: a prospective study. J Am Soc Nephrol. 2001;12:828.
14. David-Neto E, Lemos FB, Furusawa EA, et al. Impact of cyclosporin A pharmacokinetics on the presence of side effects in pediatric renal transplantation. J Am Soc Nephrol. 2000;11:343.
15. Lee YJ, Chung SJ, Shim CK. Bioequivalence of Neoplanta capsule to Sandimmune Neoral, microemulsion formulations of cyclosporin A in human subjects. Int J Clin Pharmacol Ther. 1998;36:210.
16. Tanasescu C, Serbanescu A, Spadaro A, et al. Comparison of two micro-emulsion of cyclosporine A in healthy volunteers. Eur Rev Med Pharmacol Sci. 1999;3:5.
17. Roza A, Tomlanovich S, Merion R, et al. Conversion of stable renal allograft recipients to a bioequivalent cyclosporine formulation. Transplantation. 2002;74:1013.